Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer

　　Tepotinib and osimertinib are two classes of targeted drugs that act on different key oncogenic driver pathways.Tepotinib precisely targets the MET pathway,while osimertinib targets the EGFR pathway,each with a clear and irreplaceable clinical position in the overall treatment system for non-small cell lung cancer(NSCLC).Although there is some biological association between the two in the study of tumor resistance mechanisms,no standardized combination therapy regimen has been established globally to date.

　　From a molecular mechanism perspective,cross-activation may occur between the EGFR and MET signaling pathways during tumor progression and the development of drug resistance.For example,when the EGFR pathway is continuously inhibited by drugs,the MET signaling pathway may be aberrantly activated as an alternative driver pathway,leading to continued proliferation of tumor cells.Based on this biological principle,simultaneous inhibition of both EGFR and MET pathways has certain scientific rationality in theory,which is also one of the important directions continuously explored in the field of molecular targeted therapy in recent years.

　　However,in current clinical practice,osimertinib remains the first-line standard treatment for patients with NSCLC harboring sensitive EGFR mutations.The primary indication for tepotinib is metastatic NSCLC patients with MET exon 14 skipping mutations,and it can also be used as a subsequent treatment option for patients who develop MET amplification after resistance to EGFR-targeted therapy.In the vast majority of clinical scenarios,the two drugs are used sequentially according to the patient's genetic status and treatment phase,rather than being administered simultaneously.This"stage-specific precision therapy"model is more consistent with the recommended pathways of current international mainstream clinical guidelines.

　　At the scientific research level,several early exploratory clinical trials are evaluating the efficacy and safety of the dual-targeted EGFR and MET inhibition strategy,with research focusing primarily on overcoming resistance mechanisms to EGFR-targeted therapy.However,it is important to clarify that these studies are still in the clinical exploratory phase overall,and no unified clinical conclusions have been formed.At the same time,there is a lack of large-scale,long-term safety data to support their widespread use.

　　From a safety perspective,the combined use of tepotinib and osimertinib may significantly increase the risk of treatment-related adverse reactions in patients,including increased liver function burden,higher incidence and severity of gastrointestinal reactions,and potential drug-drug interaction risks.In addition,both drugs are primarily metabolized by the liver,and their concurrent use may affect the stability of hepatic metabolic pathways,further increasing the likelihood of adverse reactions.This is one of the important reasons why the dual-targeted combination regimen has not been widely promoted in clinical practice.

　　Overall,in current medical practice,tepotinib and osimertinib are more suitable for a"sequential therapy"model rather than as a standard combination therapy regimen.In the future,with the deepening of research on EGFR resistance mechanisms and the publication of more high-quality clinical trial results,whether dual-targeted combination therapy will become the mainstream strategy for NSCLC treatment remains to be further scientifically verified.